Abstract
Background Hypertension continues to be a major challenge in developing countries like South Africa, as it significantly contributes to the cardiovascular disease burden in these countries. This study aimed to utilize the machine learning (ML) models to anticipate the incidence of hypertension in HIV patients under antiretroviral therapy (ART) in rural Eastern Cape, South Africa.
Methods This research carried out a retrospective cohort study and created and tested six machine learning algorithms: Neural Networks, Random Forest, Logistic Regression, Naive Bayes, K-Nearest Neighbours and XGBoost. The goal was to predict the likelihood of developing hypertension. Feature selection was done using the Boruta method and the model was assessed using several metrics including aiming, precision, recall, F1 score, and area under the receiver operating characteristic curve (AUC).
Results XGBoost outperformed all other models with an AUC of 0.96, which further suggests it can effectively distinguish between hypertensives and normotensives. In the case of Boruta analysis, some aggravated risk factors were age category, time on ART, BMI category, waist to hip ratio, waist size, family history of HBP and relationship status, physical activity, LDL cholesterol level, awareness of high blood pressure, education level, use of ART and diabetes mellitus.
Conclusions This study has highlighted the utility of XGBoost, as one of the advanced machine learning algorithms, in reliably forecasting the occurrence of hypertension in HIV ART patients in a rural setting. The established risk factors elucidate the complexity behind the hypertension emergence and hence the need for triad approaches which include lifestyle changes, clinical treatments, and demographic solutions to tackle the public health problem.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was fully funded by the South African Medical Research Council under its Research Capacity Development Grant (MRC-RFA-CC 01-2014).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Walter Sisulu University ethics committee, protocol number (048/ 2019) and the EC Department of Health (EC_201907_020).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.